Treatment strategy for patients with platinum-sensitive ovarian cancer using PARP inhibitors

被引：0
|
作者：
Matsumoto, Koji [1 ]
机构：
[1] Hyogo Canc Ctr, Div Med Oncol, Akashi, Hyogo, Japan
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
10.1093/annonc/mdz336
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MS3 - 3
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Ceralasertib and olaparib in the treatment of homologous recombination repair (HRR)-deficient platinum-sensitive ovarian cancer after progression on PARP inhibitors.
    Shapiro, Geoffrey I.
    Basu, Bristi
    El-Khoueiry, Anthony
    Postel-Vinay, Sophie
    Im, Seock-Ah
    Rha, Sun Young
    Friedman, Claire F.
    Italiano, Antoine
    Kim, Yong Man
    Lim, Myong Cheol
    Roux, Rene
    Liu, Joyce F.
    Sanai, Elhan
    Smith, Simon A.
    Smith, Claire
    El Farhi, Sarah
    Lau, Alan
    Lukashchuk, Natalia
    Dean, Emma
    Krebs, Matthew G.
    CANCER RESEARCH, 2022, 82 (12)
  • [22] Treatment Perspectives for Ovarian Cancer in Europe and the United States: Initial Therapy and Platinum-Sensitive Recurrence after PARP Inhibitors or Bevacizumab Therapy
    Alexandra Lainé
    Travis T. Sims
    Olivia Le Saux
    Isabelle Ray-Coquard
    Robert L. Coleman
    Current Oncology Reports, 2021, 23
  • [23] Chemotherapy-free strategy for platinum-sensitive recurrent ovarian cancer
    Zhou, Qi
    Zou, Dongling
    Long, Xingtao
    LANCET ONCOLOGY, 2019, 20 (12): : E654 - E654
  • [24] Maintenance with Trabectedin in the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer
    Guerra Alia, Eva Maria
    Sempere Ortega, Cayetano
    Cortes Salgado, Alfonso
    Sanchez Martinez, Concepcion
    Galindo Alvarez, Julio
    Perez Miez, Belen
    CASE REPORTS IN ONCOLOGY, 2019, 12 (02): : 447 - 455
  • [25] Optimizing treatment of the partially platinum-sensitive ovarian cancer patient
    Colombo, Nicoletta
    FUTURE ONCOLOGY, 2013, 9 (12) : 19 - 23
  • [26] Comparison of the Efficacy and Safety of PARP Inhibitors as a Monotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis
    Wang, Hongmei
    Wu, Meng
    Liu, Haonan
    Zhou, Hang
    Zhao, Yang
    Geng, Yifan
    Jiang, Bo
    Zhang, Kai
    Zhang, Bo
    Han, Zhengxiang
    Du, Xiuping
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [27] Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis
    Bartoletti, Michele
    Pelizzari, Giacomo
    Gerratana, Lorenzo
    Bortot, Lucia
    Lombardi, Davide
    Nicoloso, Milena
    Scalone, Simona
    Giorda, Giorgio
    Baldassarre, Gustavo
    Sorio, Roberto
    Puglisi, Fabio
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (11)
  • [28] Impact of PARP inhibitors on progression-free survival in platinum-sensitive recurrent epithelial ovarian cancer: a retrospective analysis
    Zhou, Yumei
    Xu, Junfen
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2024, 22 (01)
  • [29] PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: A cost-effectiveness analysis
    Smith, Haller J.
    Haygood, Christen L. Walters
    Arend, Rebecca C.
    Leath, Charles A., III
    Straughn, Michael, Jr.
    GYNECOLOGIC ONCOLOGY, 2015, 139 (01) : 59 - 62
  • [30] Platinum-sensitive ovarian cancer: liminal advances
    Penson, Richard T.
    LANCET ONCOLOGY, 2020, 21 (05): : 614 - 615
12345